메뉴 건너뛰기
The Lancet Diabetes and Endocrinology
Volumn 3, Issue 12, 2015, Pages 929-930
Understanding EMPA-REG OUTCOME
Author keywords

[No Author keywords available]
Indexed keywords

CYCLIC AMP; EMPAGLIFLOZIN; GLUCAGON; SAXAGLIPTIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;
EID: 84947904354     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00426-X     Document Type: Letter
Times cited : (31)
References (7)
  • 1
    • 84937053742 scopus 로고    scopus 로고
    • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    • Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015, 373:232-242. TECOS Study Group.
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, J.B.1    Bethel, M.A.2    Armstrong, P.W.3
  • 2
    • 84932619134 scopus 로고    scopus 로고
    • Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis
    • Savarese G, Perrone-Filardi P, D'Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol 2015, 181:239-244.
    • (2015) Int J Cardiol , vol.181 , pp. 239-244
    • Savarese, G.1    Perrone-Filardi, P.2    D'Amore, C.3
  • 3
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • published online Sept 17.
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015, published online Sept 17. 10.1056/NEJMoa1504720.
    • (2015) N Engl J Med
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 4
    • 84944901432 scopus 로고    scopus 로고
    • Getting to the heart of the matter in type 2 diabetes
    • The Lancet Diabetes & Endocrinology
    • Getting to the heart of the matter in type 2 diabetes. Lancet Diabetes Endocrinol 2015, 3:827. The Lancet Diabetes & Endocrinology.
    • (2015) Lancet Diabetes Endocrinol , vol.3 , pp. 827
  • 5
    • 84899882143 scopus 로고    scopus 로고
    • Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment
    • Janardhan S, Sastry GN Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment. Curr Drug Targets 2014, 15:600-621.
    • (2014) Curr Drug Targets , vol.15 , pp. 600-621
    • Janardhan, S.1    Sastry, G.N.2
  • 6
    • 84893872877 scopus 로고    scopus 로고
    • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
    • Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014, 124:499-508.
    • (2014) J Clin Invest , vol.124 , pp. 499-508
    • Ferrannini, E.1    Muscelli, E.2    Frascerra, S.3
  • 7
    • 84857408980 scopus 로고    scopus 로고
    • Minireview: glucagon in stress and energy homeostasis
    • Jones BJ, Tan T, Bloom SR Minireview: glucagon in stress and energy homeostasis. Endocrinology 2012, 153:1049-1054.
    • (2012) Endocrinology , vol.153 , pp. 1049-1054
    • Jones, B.J.1    Tan, T.2    Bloom, S.R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.